





RealRate

PHARMACEUTICAL 2020

AVADEL PHARMACEUTICALS PLC Rank 277 of 358



The relative strengths and weaknesses of AVADEL PHARMACEUTICALS PLC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of AVADEL PHARMACEUTICALS PLC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 45% points. The greatest weakness of AVADEL PHARMACEUTICALS PLC is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 152% points.

The company's Economic Capital Ratio, given in the ranking table, is -50%, being 86% points below the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	82,380
Cost of Goods Sold	12,125
Intangible Assets	19,304
Liabilities, Current	35,984
Liabilities, Non-Current	132,878
Other Assets	49,208
Other Compr. Net Income	610
Other Expenses	15,229
Other Liabilities	11,773
Other Net Income	-1,987
Other Revenues	59,215
Property and Equipment	544
Research and Development	32,917
Selling, General and Administrative Expense	30,183

Output Variable	Value in 1000 USD
Assets	151,436
Liabilities	180,635
Expenses	90,454
Revenues	59,215
Stockholders Equity	-29,199
Net Income	-33,226
Comprehensive Net Income	-32,921
Economic Capital Ratio	-50%